http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004060380-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c46b7d892a9e14908e826abab7e6430 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727 |
| filingDate | 2003-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41e52cc8a925c53f007bbe6fae322d4d |
| publicationDate | 2004-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2004060380-A1 |
| titleOfInvention | Rhamnan sulphate composition for treatment of endothelial dysfunction |
| abstract | The invention described is a method and composition for inducing cell surface anti-thrombotic activity in endothelial cells comprising administering to a patient a therapeutically-effective amount of Rhamnan Sulphate. The dose of Rhamnan sulphate is equivalentto between approximately 8,000IU and 12,000IU of heparin activit y daily on variable schedule or optionally at single dosageof 7.5 mg/kg, that is repeated on a daily basis as needed, to lo wer the incidence of thrombus formation or to lower the incidenceof hard clot formation. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007072965-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007072971-A1 |
| priorityDate | 2002-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 296.